Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II doxorubicin added to radiotherapy, temozolomide, and valproic acid for newly diagnosed high-grade gliomas
2015-002307-28Phase 2Terminated
- Sponsor
- Meyer Organics
- Start
- Nov 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin in glioblastoma (GBM), diffuse intrinsic pontine glioma (DIPG), spinal glioma and 3 more, sponsored by Meyer Organics. Primary endpoint: Safety and tolerability. Started Nov 2020; status: terminated.
02
Drugs
doxorubicin
03
Conditions
glioblastoma (GBM)diffuse intrinsic pontine glioma (DIPG)spinal gliomathalamic gliomagliomatosis cerebri (GC)
Beyond the preview
Go deeper on 2015-002307-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002307-28.